LEGEND BIOTECH CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.45 USD | +0.83% |
|
-5.33% | -21.14% |
| Apr. 23 | Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission | MT |
| Apr. 22 | Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer | MT |
Financials (USD)
| Sales 2024 * | 585M | Sales 2025 * | 1.08B | Capitalization | 8.56B |
|---|---|---|---|---|---|
| Net income 2024 * | -316M | Net income 2025 * | -92M | EV / Sales 2024 * | 13 x |
| Net cash position 2024 * | 928M | Net cash position 2025 * | 835M | EV / Sales 2025 * | 7.18 x |
| P/E ratio 2024 * |
-43.5
x | P/E ratio 2025 * |
-147
x | Employees | 1,800 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99% |
More Fundamentals
* Assessed data
More news
Latest transcript on Legend Biotech Corporation
More recommendations
More press releases
More news
| 1 day | +0.83% | ||
| 1 week | -5.33% | ||
| Current month | -15.40% | ||
| 1 month | -16.25% | ||
| 3 months | -21.94% | ||
| 6 months | -27.44% | ||
| Current year | -21.14% |
1 week
45.52
51.55
1 month
45.5259.54
Current year
45.5270.13
1 year
45.5277.32
3 years
27.7177.32
5 years
23.4177.32
10 years
23.4177.32
| Managers | Title | Age | Since |
|---|---|---|---|
Ying Huang
CEO | Chief Executive Officer | 51 | 19-06-30 |
Lori Macomber
DFI | Director of Finance/CFO | 53 | 19-08-31 |
Tracy Luo
CTO | Chief Tech/Sci/R&D Officer | - | 18-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ying Huang
CEO | Chief Executive Officer | 51 | 19-06-30 |
Corazon Sanders
BRD | Director/Board Member | 67 | 20-04-30 |
Li Zhu
BRD | Director/Board Member | 74 | 20-11-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.08% | 4 M€ | -27.92% | ||
| 1.18% | 2 M€ | -14.14% | ||
| 0.99% | 2 M€ | -18.98% | - | |
| 0.95% | 11 M€ | -6.03% | - | |
| 0.58% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 47.06 | +1.88% | 756,637 |
| 24-04-19 | 46.19 | -1.97% | 1,253,875 |
| 24-04-18 | 47.12 | -3.50% | 816,010 |
| 24-04-17 | 48.83 | -2.57% | 1,411,963 |
| 24-04-16 | 50.12 | -3.07% | 2,695,726 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Calendar
2024-05-12
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
47.06
USD
Average target price
86.33
USD
Spread / Average Target
+83.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.14% | 8.56B | |
| -0.49% | 103B | |
| +3.31% | 96.73B | |
| +1.66% | 21.31B | |
| -16.16% | 21.21B | |
| -6.82% | 18.79B | |
| -41.41% | 16.37B | |
| -22.87% | 13.68B | |
| +6.32% | 13.44B | |
| +21.46% | 10.98B |
- Stock Market
- Equities
- LEGN Stock
